noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

U.S. Senate Committee on Commerce,[...]

Cantwell, Blackburn, Blunt Rochester Introduce Bipartisan Bill to[...]
City of Garland, TX

City of Garland Looks to Score Professional and Youth Soccer Complex,[...]
CSD - Cosumnes Community Services[...]

Overnight Warming Location Open

Healthcare

Innate Pharma SA

01/27/2025 | Press release | Distributed by Public on 01/27/2025 00:01

Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors

Read this content

Click here to read the original version at the source's official website. The text of this article is not available at the moment.

Sharing and Personal Tools

Please select the service you want to use:

Smartlinks | Innate Pharma SA | News | Health | Biotechnology | Technology | Biotechnology | Science | Biotechnology | Research | Company News | Business Announcement | Products and Services | Securities Issuers | Biotechnology and Medical Research Companies | London Stock Exchange (LSE) | Frankfurt Stock Exchange | Berlin Stock Exchange | Dusseldorf Stock Exchange | Munich Stock Exchange | Stuttgart Stock Exchange | OTC Markets | Tradegate Exchange | NYSE American | NYSE ARCA Equities | Euronext Paris | Nasdaq Global Select Market | Cboe BZX Exchange | Cboe BXE Europe | Cboe CXE Europe | Cboe Off Exchange | Cboe BYX Exchange | Cboe EDGA Exchange | Cboe EDGX Exchange | NYSE National | FINRA Alternative Display Facility (ADF) | Aquis Exchange | SIGMA X MTF | EuroTLX | Aquis Exchange Europe | Equiduct | Nasdaq BX | Nasdaq PSX | NYSE Chicago | Turquoise

Back